Skip to main content
HUAPONT LIFE SCIENCES CO., LTD. logo

HUAPONT LIFE SCIENCES CO., LTD. — Investor Relations & Filings

Ticker · 002004 ISIN · CNE000001JJ6 LEI · 3003009TGXJC0JJVTJ07 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,461 across all filing types
Latest filing 2018-04-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002004

About HUAPONT LIFE SCIENCES CO., LTD.

https://www.huapont.com.cn

HUAPONT LIFE SCIENCES CO., LTD. operates as a diversified entity specializing in the research, development, manufacturing, and distribution of pharmaceutical and chemical solutions. The company holds a prominent position in the dermatology sector, providing a comprehensive range of therapeutic products for various skin disorders. Its pharmaceutical operations extend to the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Beyond human health, the organization maintains a significant footprint in the agrochemical sector, focusing on the development and supply of crop protection products, including herbicides and pesticides. The company also integrates healthcare services into its business model, overseeing the operation of medical facilities and specialized clinics. Its strategic focus centers on technological advancement and the maintenance of a robust supply chain to support its global commercial activities.

Recent filings

Filing Released Lang Actions
关于公司2018年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the fiscal year 2018. It includes descriptions of the nature of transactions, involved related parties, transaction amounts, pricing policies, and independent directors' opinions. The document is not a full financial report but a specific disclosure about related party transactions, which is a regulatory announcement. It does not contain comprehensive financial statements or management discussion and analysis. It is not an annual or interim report, nor an earnings release. The document is longer than 5,000 characters and provides substantive information about related party transactions, which is typically filed as a Regulatory Filing (RNS) in the absence of a more specific category. Therefore, the best classification is Regulatory Filings (RNS).
2018-04-27 Chinese
关于召开2017年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2017 Annual General Meeting (AGM) of 华邦生命健康股份有限公司, including the date, time, venue, voting procedures (both in-person and online), agenda items to be discussed and voted on, and instructions for shareholders. It includes references to the 2017 Annual Report and other reports to be reviewed at the meeting, but the document itself is not the report or the voting results. It is a formal notification to shareholders about the AGM and the matters to be considered. The document length is about 6373 characters, which is consistent with a detailed meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2018-04-27 Chinese
北京市时代九和律师事务所关于公司回购部分社会公众股份的法律意见书
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's share repurchase (buyback) of some of its publicly held shares. It discusses the legal compliance, approvals, authorizations, and disclosure obligations related to the share repurchase. The document references relevant laws and regulations, the board and shareholder approvals, and confirms the legality and funding source of the repurchase. It does not contain financial statements or earnings data, nor is it a report or announcement of voting results. It is a legal opinion specifically about the share repurchase transaction. Therefore, the document fits best into the category of Transaction in Own Shares (POS), which covers reports related to the company buying back its own shares.
2018-04-27 Chinese
2017年年度报告（已取消）
Annual Report Classification · 100% confidence The document is titled as the "2017 Annual Report" of 华邦生命健康股份有限公司 (Huapont Life Sciences Co., Ltd.) and dated April 2018. It contains detailed sections including company overview, financial data, management discussion and analysis, governance, and a full financial report section. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial data, quarterly breakdowns, non-recurring items, and detailed company information confirms this is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2017
2018-04-27 Chinese
西南证券股份有限公司关于公司向特定对象发行股份购买资产并募集配套资金暨关联交易2017年度业绩承诺实现情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion on the performance commitment realization of specific asset purchase transactions by Huabang Life Health Co., Ltd. It includes detailed financial data, audit reports, and performance commitment fulfillment for the years 2013 to 2017. The content focuses on the verification of performance commitments related to asset acquisitions and associated compensation mechanisms, which is typical of an Audit Report or Information related to compliance with regulatory requirements on major asset restructuring and performance guarantees. The document is not a full annual report, earnings release, or management discussion but a specialized audit-type report on performance commitments. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2017
2018-04-27 Chinese
关于2017年度内部控制自我评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-assessment report for the fiscal year 2017 by 华邦生命健康股份有限公司. It contains detailed descriptions of the company's internal control systems, evaluation scope, control areas such as governance, organizational structure, subsidiary management, sales, procurement, asset management, financial management, and internal audit. It also includes internal control defect recognition standards and the company's evaluation conclusions stating no major defects were found. The document is comprehensive, contains substantive content related to internal control evaluation, and is not merely an announcement or certification. It is not a full annual report (10-K) but a standalone internal control evaluation report, which fits the category of Audit Report / Information (AR). The length (8100 characters) and detailed content confirm it is a full report, not just an announcement or summary. FY 2017
2018-04-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.